A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2002
This is a Phase IIIb, randomized, double-blind, parallel-group, placebo-controlled, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Epistemonikos ID: d68753f3fab9f36ebf1e385245d8567166fb8204
First added on: May 04, 2024